

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
03 AUG 14 PM 1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name Pfizer, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 325 7th Street, N.W. Suite 1200 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name M. Kenneth Bowler	Telephone (202) 783-7070	E-mail (optional)	5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31354000


TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,840,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate reporting method. See instructions for description of method.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature  _____ Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations _____ Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues
HR 2673, Agriculture Appropriations, pharmaceutical counterfeiting, importation
S 1, Prescription Drug and Medicare Improvement Act of 2003, pharmaceutical counterfeiting, importation
S 1427, Agriculture Appropriations, pharmaceutical counterfeiting, importation


17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None



Signature  _____ Date **8/14/2003**

Printed Name and Title **M. Kenneth Bowler - Vice President, Federal Government Relations** _____ Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

HR 1, Medicare Prescription Drug and Modernization Act of 2003, pharmaceutical counterfeiting, importation
HR 2673, Agriculture Appropriations, pharmaceutical counterfeiting, importation
S 1, The Prescription Drug and Medicare Improvement Act of 2003, pharmaceutical counterfeiting, importation
S 1427, Agriculture Appropriations, pharmaceutical counterfeiting, importation


17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None




Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page _____

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues


HR 2427 , Pharmaceutical Market Access Act of 2003, pharmaceutical counterfeiting, importation
S 54, The Greater Access to Affordable Pharmaceuticals Act of 2003, patent issues
S 7, The Prescription Drug Benefit and Cost Containment Act of 2003, patents, pharmaceutical counterfeiting, importation

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2003

Printed Name and Title **M. Kenneth Bowler - Vice President, Federal Government Relations** Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues
S 2427, Pharmaceutical Market Access Act of 2003, pharmaceutical counterfeiting, importation Prescription and over the counter pharmaceuticals (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

HR 1, The Medicare Prescription Drug and Modernization Act of 2003, Medicare prescription drug benefit, counterfeit, importation

HR 2427, Pharmaceutical Market Access Act of 2003, pharmaceutical counterfeit, importation

S 1, The Prescription Drug and Medicare Improvement Act of 2003, Medicare prescription drug benefit, counterfeit, importation

S 54, Greater Access to Affordable Pharmaceuticals Act of 2003, access to pharmaceuticals, patents

S 7, The Prescription Drug Benefit and Cost Containment Act of 2003, access to pharmaceuticals, patents, counterfeit, importation

17. House(s) of Congress and Federal agencies contacted Check if None


**Department of Health & Human Services
Executive Office of the President
Food & Drug Administration
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None



Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

HR 1, The Medicare Prescription Drug and Modernization Act of 2003, Prescription drug benefit, patents, counterfeiting, importation

S 1, The Prescription Drug and Medicare Improvement Act of 2003, Prescription drug benefit, patents, count importation

S 7, The Prescription Drug Benefit and Cost Containment Act of 2003, Prescription drug benefit, patents, count importation

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

HR 2122, The Project BioShield Act of 2003, Pharmaceutical reasearch and development, security
S 1504, The Project BioShield Act of 2003, Pharmaceutical research and development, security

17. House(s) of Congress and Federal agencies contacted

Check if None

Department of Commerce
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bowler, M. Kenneth	
Judge, Dolly	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues
**no bills, , International repatriation tax
S 477, Preserving Drug Discounts Act of 2003, tax deductions**

17. House(s) of Congress and Federal agencies contacted Check if None
**House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TOR (one per page)

16. Specific Lobbying issues
S 1125, The Fairness in Asbestos Injury Resolution Act of 2003, asbestos litigation

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bagger, Rich	
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None



Signature  Date 8/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page _____

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

HR 1298, United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, access to pharmaceutical market access
HR 2738, The United States-Chile Free Trade Agreement Implementation Act of 2003, intellectual property market access

HR 2739, The United States-Singapore Free Trade Agreement Implementation Act of 2003, intellectual property protection, market access

International intellectual property protection (no bills)

International pharmaceutical market access (no bills)

WTO accession and implementation issues (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Commerce**
- Department of State**
- Executive Office of the President**
- House of Representatives**
- Office of U.S. Trade Representative**
- Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature:  Date **8/14/2003**

Printed Name and Title **M. Kenneth Bowler - Vice President, Federal Government Relations** Page